Gallbladder polyps and gallbladder cancer

01OverviewDefinition, clinical context and the essential points that orientate the chapter.

'Gallbladder polyp' is an imaging description, not a histological diagnosis. Cholesterol polyps and inflammatory pseudopolyps are frequent and often harmless; adenomas and malignant polypoid tumours are much less common. A fold, adherent sludge or small calculus may mimic a lesion. Management weighs reliable size and morphology against growth, primary sclerosing cholangitis, age, symptoms plausibly attributable to the gallbladder, operative risk and what surveillance could achieve. The same ultrasound measurement can vary between observers, so apparent small growth should be confirmed before irreversible treatment.

Gallbladder adenocarcinoma commonly infiltrates the wall rather than forming a neat pedunculated polyp. It may be discovered as focal thickening, a mass replacing the gallbladder, invasion into adjacent liver or as unexpected histology after surgery for stones. Symptoms overlap with benign gallstone disease; persistent pain, constitutional change, a palpable mass or progressive obstruction should trigger cancer investigation. Jaundice can indicate hilar or duct invasion and often implies more advanced anatomy, but it still requires urgent relief if infection develops.

The correct pathway protects staging and resectability. High-quality ultrasound is followed by contrast CT and often MRI/MRCP according to specialist advice; selected patients need additional staging or laparoscopy. Surgery offers the only realistic cure when disease is localised, but the extent differs from ordinary laparoscopic cholecystectomy. Tissue acquisition should be decided by the MDT because an approach that traverses the peritoneum or a potentially resectable tumour can create avoidable seeding or confusion. Advanced disease care integrates biliary drainage, systemic treatment, symptom control, nutrition and early palliative support.

Key points

Most small gallbladder polypoid lesions are benign cholesterol deposits, but size, sessile morphology, focal wall thickening, interval growth and patient risk factors influence malignancy concern.
Ultrasound reports should document maximum diameter, attachment, mobility, acoustic shadowing, adjacent wall and comparison with prior imaging; stones move and shadow, whereas a true polyp remains attached.
Do not memorise one universal operation or surveillance threshold: apply the current network radiology and HPB policy, because measurement variability and accepted algorithms can change.
Primary sclerosing cholangitis, increasing age, a sessile lesion or associated focal wall thickening can lower the threshold for specialist discussion; decisions still require individual surgical fitness and preference.
Gallbladder cancer is often clinically silent or found unexpectedly after cholecystectomy; later disease may cause persistent right-upper-quadrant pain, weight loss, jaundice, anorexia or an abdominal mass.
A suspicious mass or concerning polyp needs contrast cross-sectional staging and specialist HPB MDT review, not casual transperitoneal biopsy or routine simple cholecystectomy without an oncological plan.
Fever and jaundice may reflect cholangitis caused by malignant obstruction and require emergency antibiotics and biliary drainage independently of the cancer timetable.
Histology after every cholecystectomy must be reviewed and acted upon; an incidental tumour can require completion staging and additional liver or nodal surgery at a specialist centre.

02AetiologyUnderlying causes, associations and risk factors, with why each one matters.

Cholesterol polyps

Most small polypoid lesions are benign cholesterol deposits caused by lipid-laden macrophages within the gallbladder mucosa rather than true neoplasia.

Neoplastic epithelial lesions

Adenomas and dysplastic lesions can progress towards adenocarcinoma through accumulated epithelial alterations, with risk linked to morphology and growth.

Higher-risk biliary context

Primary sclerosing cholangitis, increasing age, sessile morphology and focal wall thickening increase concern, while most gallbladder cancers remain sporadic.

03PathophysiologyThe causal sequence from the underlying abnormality to symptoms and harm.

1
Mucosal proliferation
Cholesterolosis or epithelial proliferation creates a fixed lesion attached to the gallbladder wall rather than a mobile shadowing stone.
2
Dysplasia and invasion
Neoplastic cells acquire invasive capacity, cross the thin gallbladder wall and readily enter adjacent liver or lymphatics.
3
Biliary and metastatic spread
Advanced tumour obstructs ducts, invades hilar structures and disseminates to nodes, peritoneum or distant organs, often before symptoms become specific.

04Clinical features and red flagsSymptoms, examination findings, patterns of presentation and time-critical warnings.

Likely benign polypoid finding

A small, stable, pedunculated-appearing, non-shadowing lesion without wall thickening or symptoms is often cholesterol-related, subject to local surveillance rules.

Higher-risk morphology

Larger measured diameter, sessile attachment, focal adjacent wall thickening or convincing interval enlargement warrants prompt radiology review and HPB decision-making.

Cancer symptom complex

Persistent right-upper-quadrant discomfort, unexplained weight loss, anorexia, progressive jaundice or an upper-abdominal mass should not be attributed automatically to uncomplicated stones.

Incidental postoperative cancerRed flag

Unexpected adenocarcinoma in a cholecystectomy specimen requires staging, pathology review and specialist MDT discussion before assuming the original operation was sufficient.

Malignant biliary sepsisRed flag

Rigors, fever, hypotension or confusion with tumour-related jaundice is an emergency cholangitis presentation requiring resuscitation and drainage alongside oncological care.

05InvestigationsWhat to request, why it matters and how to interpret it.

Investigation order

Read from the initial assessment onwards. Tests may run in parallel in urgent care; first-line, preferred, confirmatory, definitive and gold-standard labels appear only when the chapter explicitly states them.

01
Expert transabdominal ultrasoundFirst step
Why
Characterise lesion size, morphology, mobility, shadowing, wall change, gallstones and biliary dilatation with prior-image comparison.
Interpretation and limitations
A fixed non-shadowing projection supports a polypoid lesion, but adherent sludge and folds mimic disease; management uses the network's current measurement protocol.
02
Repeat targeted ultrasound
Why
Confirm questionable size or growth and provide surveillance when current local criteria favour observation.
Interpretation and limitations
True progressive change is more concerning than a single borderline value, but apparent millimetre differences may reflect technique, distension or reader variation.
03
Contrast CT chest, abdomen and pelvis
Why
Stage a suspicious gallbladder mass, assess liver invasion, nodes, vessels and distant disease, and support resectability review.
Interpretation and limitations
A mass replacing the gallbladder, direct hepatic extension or metastatic deposits indicates more than routine stone surgery; subtle early wall cancer can remain difficult.
04
MRI and MRCP
Why
Define local soft-tissue and biliary involvement when CT or ultrasound suggests malignancy or obstructive anatomy.
Interpretation and limitations
Duct extension and liver interface guide HPB planning; imaging should ideally precede non-emergency stenting that could obscure baseline anatomy.
05
Liver profile, FBC and renal function
Why
Identify cholestasis, anaemia, infection and organ function relevant to contrast, drainage, surgery and systemic therapy.
Interpretation and limitations
Normal liver tests do not exclude an early gallbladder-wall tumour; inflammatory or cholestatic deterioration changes urgency.
06
Histopathology and MDT pathology review
Why
Confirm tumour type, depth, margins and other features after resection or appropriately planned tissue acquisition.
Interpretation and limitations
Tumour stage and margin status determine whether a simple cholecystectomy is adequate or completion oncological surgery should be considered.

06Differential diagnosisRealistic alternatives and the features that help distinguish them.

Gallstone or sludge

A stone usually moves and casts an acoustic shadow, while sludge shifts slowly; a true polyp remains attached and non-shadowing on careful ultrasound.

Adenomyomatosis

Characteristic wall thickening, intramural sinuses and comet-tail artefact support a benign hyperplastic process rather than a discrete neoplastic polyp.

Cholecystitis or metastatic lesion

Diffuse inflammatory wall change with pain and fever suggests cholecystitis, while known cancer and atypical multiplicity raise secondary involvement.

07ManagementImmediate care, first-line treatment, alternatives and escalation.

01IncidentalPolyp risk assessmentFirst stepUltrasound reports a polypoid gallbladder lesion without a definite invasive mass.

1Verify the image quality, maximum size, sessile or pedunculated morphology, focal wall thickening and comparison with every prior scan.
2Record primary sclerosing cholangitis, age, symptoms, gallstones, comorbidity and whether the person could benefit from future surgery.
3Apply the current local radiology-HPB algorithm to choose discharge, interval ultrasound or surgical consultation, documenting the version used.
4EscalationEscalate discordant measurements, convincing growth or suspicious morphology for specialist imaging rather than repeatedly resetting surveillance.

02SuspiciousPossible gallbladder malignancyA mass, invasive wall thickening, progressive jaundice or systemic cancer features raises serious concern.

1Arrange urgent specialist HPB referral, liver and renal blood tests, and staging-quality contrast CT with additional MRI or MRCP as advised.
2Discuss at the regional MDT before percutaneous biopsy, ERCP sampling or non-oncological surgery when the patient is stable enough to preserve planning.
3Treat cholangitis, gastric outlet symptoms, pain, pruritus and malnutrition promptly while staging and fitness assessments proceed.
4Use shared decision-making to consider oncological resection, systemic treatment, trials or symptom-focused care according to stage and performance status.

03HistologyCancer after cholecystectomyRoutine pathology unexpectedly identifies gallbladder carcinoma in a removed specimen.

1Notify and support the patient promptly, ensure expert pathology review and retrieve the operative record, specimen handling and any bile-spillage details.
2Obtain complete staging imaging through the HPB cancer service and avoid assuming that a negative preoperative ultrasound excludes residual disease.
3Let the specialist MDT decide whether observation, completion liver and lymph-node surgery, systemic treatment or another strategy is appropriate.
4Provide a named cancer nurse contact and communicate surveillance, treatment dates and recurrence warning symptoms across primary and secondary care.

Key medicines and prescribing safety3 treatments · regimens, roles and cautions

Controls persistent tumour or postoperative pain while staging and disease-directed treatment proceed.

Analgesic ladder for cancer-related pain

Select regular non-opioid and, when needed, opioid regimens from the current BNF with individual titration and breakthrough provision.

Review renal and hepatic function, constipation, nausea, sedation and driving; new escalating pain also warrants anatomical reassessment rather than dose escalation alone.

Treats systemic bacterial infection as a bridge to source control in an obstructed patient.

Antibiotics for tumour-associated cholangitis

Give the local emergency biliary-infection regimen at current BNF doses and arrange urgent drainage when malignant obstruction is infected.

Do not confuse antimicrobial response with cancer treatment or durable duct patency; adjust for cultures, allergy, renal function and prior stents.

May be offered after surgery or for unresectable or metastatic gallbladder cancer according to stage, biomarkers and fitness.

Systemic anticancer therapy

Use only an MDT-selected, nationally commissioned oncology protocol with cycle dosing calculated and verified by the treating cancer service.

Regimens and approvals evolve; assess marrow, kidney, liver, infection, neuropathy and immune toxicity risks and never start from a textbook summary.

08ComplicationsImportant consequences, why they occur and why they matter clinically.

Local hepatic invasion

The gallbladder's thin wall permits early extension into adjacent liver and hilar structures, reducing the opportunity for curative resection.

Biliary obstruction and cholangitis

Tumour involving the hilum or common duct causes jaundice, pruritus and infected obstruction requiring specialist drainage planning.

Metastatic and nutritional decline

Nodal, peritoneal and distant spread causes pain, ascites, anorexia and weight loss, limiting tolerance of systemic or surgical treatment.

09Monitoring and follow-upTreatment response, safety checks and longer-term review.

Use the exact surveillance interval and stopping criteria in the current local gallbladder-polyp protocol, not an outdated remembered threshold.
Compare serial ultrasound measurements side by side and request radiology adjudication when small reported growth would change treatment.
After cancer surgery, follow the regional oncological surveillance schedule and act on weight loss, jaundice, fever or new persistent pain.
For biliary stents, track bilirubin, symptoms and exchange ownership; recurrent rigors require emergency assessment for occlusion.
During systemic therapy, the oncology service monitors blood counts, organ function, infection and regimen-specific toxicities before each cycle.

10Special situationsVariants, exceptions and circumstances that change the usual approach.

Polyp is descriptive

Ultrasound cannot reliably provide histology, so the report begins risk stratification rather than concluding benignity or cancer.

Millimetres can be noise

Gallbladder distension, scanning plane and observer technique can create apparent growth near a management boundary.

Wall cancer hides

Infiltrative adenocarcinoma may appear as asymmetric thickening rather than a discrete intraluminal polyp.

Routine histology protects

Unexpected malignancy after apparently benign cholecystectomy is actionable only if the pathology result reaches a responsible team.

Biopsy route matters

Tissue is valuable, but an unplanned needle path can create seeding risk or complicate a potentially curative operation.

11Common pitfallsFrequent interpretation and management errors.

01
Applying a remembered international polyp threshold without checking the current network policy.
02
Equating a one-millimetre reported difference with certain biological growth.
03
Treating focal wall thickening as uncomplicated cholesterol polyps without specialist review.
04
Performing simple cholecystectomy for a suspected invasive mass outside oncological planning.
05
Obtaining percutaneous tissue before discussing a potentially resectable lesion at HPB MDT.
06
Failing to follow up unexpected carcinoma in the cholecystectomy pathology report.